[Adverse reactions of different treatments in chronic hepatitis C].
Hepatitis C virus infection is estimated to affect over 170 million people worldwide. Standard treatment for chronic HCV involves an interferon-based preparation and ribavirin for 24 to 48 weeks. These therapeutic regimens are associated with numerous adverse events, among which constitutional and neuropsychiatric symptoms, as well as hematological abnormalities, stand out. Adverse events resulting from the treatment of hepatitis C can jeopardize the quality of life of patients and their response to treatment. The control of those events involves medicinal and non-medicinal interventions. The latter include a reduction in the dosage of IFN or RBV and discontinuation of the treatment.
Luca
Cătălina
C
Disciplina de Boli infecţioase, Facultatea de Medicină, Universitatea de Medicină si Farmacie "Gr.T. Popa" Iaşi.
Grigore
Lucia
L
Vâţă
A
A
Dorobăţ
Carmen
C
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001327:Autoimmune Diseases / Q000139:chemically induced; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced; D004359:Drug Therapy, Combination; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D001523:Mental Disorders / Q000139:chemically induced; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a